NMN (nicotinamide mononucleotide) is a nucleotide derived from ribose and nicotinamide that serves as a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme involved in hundreds of biological reactions including cellular energy production, DNA repair, and immune function. NMN is found naturally in small amounts in foods such as edamame, broccoli, cucumber, and avocado, but supplemental doses are required to meaningfully raise NAD+ levels. 

• NMNH (dihydronicotinamide mononucleotide) is the reduced form of NMN, differing by a single added hydrogen atom on the nicotinamide ring. This structural change allows it to bypass key rate-limiting steps in NAD+ biosynthesis (NAMPT and NRK), making it a potentially faster-acting and more potent NAD+ precursor. 

Both are NAD+ precursors but follow different metabolic pathways. NMNH is in a reduced (electron-rich) state and may produce NAD+ faster and at higher concentrations. 

 Animal studies suggest NMNH can raise NAD+ levels in tissues where NMN shows limited impact, including skeletal muscle, heart, and brain. NMNH may increase intracellular NAD+ levels up to 4–10× more than NMN at equivalent doses, with faster onset (15–30 minutes) and longer duration (up to 24 hours). 

By supporting NAD+ production, NMN may help maintain mitochondrial function, support DNA repair, promote healthy metabolic function, and support cellular resilience—especially as NAD+ naturally declines with age. 

Preclinical research suggests NMNH may increase intracellular NAD+ levels more than NMN at equivalent doses, with potential benefits including faster energy metabolism support, DNA repair activation, cellular health optimization, and protective effects against oxidative stress. 

Nexergy™ NMN is NMN processed into an amorphous (disordered, non-crystalline) solid state instead of the usual crystalline powder. This altered physical structure is intended to enhance dissolution rate and bioavailability compared with standard crystalline NMN. 

 Nexergy+™ NMNH is an amorphous form of NMNH designed to enhance dissolution and absorption. It uses a disordered structure instead of a crystalline lattice to improve solubility and bioavailability for more efficient NAD+ support. 

Regular NMN and NMNH are crystalline, with molecules arranged in a repeating lattice. Nexergy™ NMN and Nexergy+™ NMNH are amorphous and lack this ordered structure, often showing higher apparent solubility and faster dissolution, which may support more efficient uptake depending on the final formulation. 

NMN: Low- to mid-hundreds of milligrams per day (depending on product and intended use)  

NMNH: Clinical research has studied 125 mg, 250 mg, and 500 mg daily for 90 days, with all doses showing NAD+ increases and good tolerability. 

Nexergy™ NMN & Nexergy+™ NMNH: Generally align with their respective dosing ranges  

Always follow product label instructions and consult a healthcare provider for personalized guidance. 

Most clinical trials and practitioners recommend taking NMN or NMNH in the morning, as NAD+ plays a key role in circadian rhythm regulation and mitochondrial energy production—aligning supplementation with daytime metabolic activity. Both can be taken with or without food; some individuals split doses (morning and early afternoon) to maintain more consistent NAD+ support throughout the day, especially at higher doses. 

Yes, but with consideration. NMN and NMNH are commonly paired with trans-resveratrol (which activates SIRT1 synergistically with NAD+), TMG (trimethylglycine, to support healthy methylation at higher doses), and other longevity-supportive nutrients such as CoQ10, omega-3 fatty acids, and Vitamin D3+K2. Both can be part of a broader longevity routine including exercise, sleep, and metabolic support. When stacking multiple NAD+ precursors, total niacin-related intake can accumulate—approach stacking cautiously and seek professional guidance for optimal combinations. 

NMN & NMNH: Both are supported by peer-reviewed research demonstrating NAD+ elevation and cellular benefits. 

Nexergy™ NMN & Nexergy+™ NMNH: Supported by broader NMN/NMNH research and pharmaceutical literature on amorphous delivery systems. UthPeak® NMNH currently has the only published Phase I trial for a branded NMNH ingredient; Nexergy+™ NMNH does not yet have ingredient-specific human clinical trials.